Literature DB >> 26214042

The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer.

Zhenxin Wang1, Jinlian Zhu, Haidi Gu, Yuan Yuan, Bin Zhang, Dongming Zhu, Jian Zhou, Yibei Zhu, Weichang Chen.   

Abstract

AIM: To investigate the clinical significance of Tim-3 (T-cell immunoglobulin- and mucin-domain-containing molecule 3) expression in natural killer (NK) cells from patients with gastric cancer.
MATERIALS AND METHODS: Sixty-two patients with gastric cancer and 32 healthy controls were recruited for this study. Tim-3 expression in peripheral blood samples was analyzed using flow cytometry. The expression pattern of Tim-3 on NK cells was also confirmed using a gastric cancer-bearing mouse model. To further investigate the mechanisms that regulate Tim-3 expression, T-bet(-/-), Eomes(-/-), and Eomes/T-bet double knockout mice were utilized. Additionally, we statistically analyzed the clinical significance of Tim-3 expression on NK cells.
RESULTS: We found that the levels of Tim-3 in NK cells obtained from patients with gastric cancer were significantly higher than the levels in healthy controls. Clinical analyses showed that Tim-3 levels on NK cells were associated with advanced tumor stage. In a tumor-bearing mouse model, Tim-3 levels in NK cells increased with tumor growth, indicating that tumor progression could induce Tim-3 expression in NK cells. Finally, we report that T-bet is a key factor involved in regulating Tim-3 expression.
CONCLUSION: Our data indicate that Tim-3 expression on NK cells is regulated by T-bet, and that Tim-3 levels correlate with advanced stages of gastric cancer.

Entities:  

Keywords:  T-bet; Tim-3; gastric cancer; natural killer cells; tumor progression

Mesh:

Substances:

Year:  2015        PMID: 26214042     DOI: 10.3109/08820139.2015.1052145

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  26 in total

Review 1.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 2.  Tim-3 and its role in regulating anti-tumor immunity.

Authors:  Madhumita Das; Chen Zhu; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

3.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

Review 4.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

5.  Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

Authors:  Keiko Nagahara; Tomohiro Arikawa; Souichi Oomizu; Keiichi Kontani; Atsuya Nobumoto; Hiroaki Tateno; Kota Watanabe; Toshiro Niki; Shigeki Katoh; Minoru Miyake; Syun-Ichiro Nagahata; Jun Hirabayashi; Vijay K Kuchroo; Akira Yamauchi; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

Review 6.  Immune Regulation and Antitumor Effect of TIM-1.

Authors:  Peng Du; Ruihua Xiong; Xiaodong Li; Jingting Jiang
Journal:  J Immunol Res       Date:  2016-06-20       Impact factor: 4.818

Review 7.  Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.

Authors:  Hyung-Joon Kwon; Nayoung Kim; Hun Sik Kim
Journal:  Exp Mol Med       Date:  2017-03-31       Impact factor: 8.718

Review 8.  Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers.

Authors:  Ross King; Conall Hayes; Claire L Donohoe; Margaret R Dunne; Maria Davern; Noel E Donlon
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 9.  Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.

Authors:  Nayoung Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.